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mental cost of €496, resulting in an incremental cost-effectiveness
ratio of €5470/LYG. LYG and incremental costs were respec-
tively most sensitive to time-horizon and the effect of Hexvix on
recurrence rate (€3,251/LYG to €25,549/LYG). CONCLUSION:
Compared to standard white light cystoscopy alone, in this hypo-
thetical model adding Hexvix to this procedure appears to be
cost-effective in Belgium from the health care payer’s perspective.
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OBJECTIVES: To determine the cost-effectiveness of sunitinib
malate versus best supportive care (BSC) after failure of cytokine
immunotherapy from the perspective of the Belgian public payers
(INAMI/RIZIV). METHODS: A Markov model was constructed
to simulate disease progression after failure on ﬁrst-line cytokine
therapy. Patients entered the model receiving sunitinib plus BSC
or BSC alone. The model had 3 disease states (progression-free
survival, tumor progression and move to BSC, and death) and
used monthly cycles. Outcomes in the model were valued in
terms of progression-free life years (PFLYs) and life years (LYs)
gained. The cost-effectiveness measures were cost per PFLY and
cost per LY saved. The effectiveness parameters for sunitinib
were taken from a phase II clinical trial (RTKC-0511-014). To
estimate survival for patients receiving palliative/supportive care,
data from a SEER-Medicare analysis and a study of previously-
treated patients with mRCC who were candidates for second-line
therapy (Motzer et al., 2004) were combined. Medical costs in
2006 prices were considered from the perspective of the RIZIV/
INAMI. Resource utilization was based on expert opinion from
a modiﬁed Delphi panel consisting of seven Belgian physicians
specialized in mRCC. Utilities were derived from published lit-
erature. The model incorporates the expensive cost of the termi-
nal stage (last 4 weeks of life). Future costs were discounted at
3% and effects at 1.5% in line with the Belgian pharmacoeco-
nomic guidelines. The time horizon was lifetime (10 years).
RESULTS: Treatment with sunitinib was associated with an
average gain of 5.13 PFLYs and 1.11 LYS per patient. The
incremental cost-effectiveness ratio of sunitinib versus BSC was
€7,665 per PFLY and €35,389 per LY gained. CONCLUSION:
Given the assumptions and limitations of this model, if the value
of a life year gained for cytokine-refractory mRCC patients is at
least €35,389 sunitinib should be considered a cost-effective
therapy.
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OBJECTIVES: Primary prophylaxis with granulocyte-colony
stimulating factors, used in the ﬁrst and subsequent cycles of
chemotherapy, is recommended by the 2006 ASCO and EORTC
guidelines when the overall risk of febrile neutropenia (FN)
is 20%. We evaluated the cost-effectiveness of pegﬁlgrastim
versus ﬁlgrastim used for 11 days (as used in clinical trials) and
6 days (often used in clinical practice) in patients with aggressive
non-Hodgkin’s lymphoma (NHL) receiving CHOP-21 chemo-
therapy in Italy. METHODS: A decision-analytic model was
constructed from a health care payer’s perspective with a life-
time model horizon. Costs (2006 value) including drugs, drug
administration, FN-related hospitalisations, and subsequent
medical costs were acquired from ofﬁcial price lists or literature.
FN risk, FN case-fatality, relative dose intensity (RDI), and
impact of RDI on survival were based on data from a compre-
hensive literature review and expert panel validation. Using data
from a meta-analysis and several observational studies, we esti-
mated that the absolute risk of FN in patients receiving peg-
ﬁlgrastim decreased from 19.6% to 13.1% (6.5 percentage
points) versus 11-day ﬁlgrastim, and from 25.1% to 13.1% (12
percentage points) versus 6-day ﬁlgrastim. NHL mortality and
all-cause mortality were from literature. Sensitivity analyses were
performed on key parameters. RESULTS: Pegﬁlgrastim was cost
saving compared with 11-day ﬁlgrastim (€5053 versus €7465).
Compared with 6-day ﬁlgrastim, the incremental cost-
effectiveness ratio (ICER) was €475 per FN event avoided or €5
per 1% decrease in absolute risk of FN. Pegﬁlgrastim achieved
0.112 more discounted life-years (LY) at a minimal cost increase
of €57 (€5053 versus €4996) per person, yielding an ICER of
€513/LY gained. Results were most sensitive to the relative risk of
FN for ﬁlgrastim versus pegﬁlgrastim. CONCLUSION: In Italy,
pegﬁlgrastim was cost saving compared with 11-day ﬁlgrastim
and appeared to be cost-effective compared with ﬁlgrastim used
for 6 days per cycle of CHOP-21.
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OBJECTIVES: To study the incremental cost-effectiveness of
two 5HT3 receptor antagonists-granisetron (GR) against
ondansetron (ON)- in prevention treatment of Chemotherapy
induced nausea and vomiting (CINV). METHODS: Prospective,
multi-center, observational study on 325 naïve patients recruited
at 8 Spanish Oncology Services. Consecutive patients undergoing
1st cycle with moderate to highly emetogenic chemotherapy,
and scheduled antiemetic treatment based on GR or ON were
enrolled. After chemotherapy (day 0), daily maximum nausea
intensity and number of vomiting episodes were self-recorded
during 5 more days in a diary card. Acute CINV was deﬁned as
developed in day 0, and delayed CINV as developed or persisting
in days 1–5. Antiemetic “full” response was deﬁned as: no emesis
and no/mild nausea. Differences between GR and ON in adverse
event costs, emergency visits, or other concomitant treatments
were negligible. Only antiemetic drug direct costs were consid-
ered. Incremental Cost-Effectiveness Ratio (ICER) was computed
for 1,000 and 10,000 bootstrap samples. Mean ICER values,
bootstrap percentiles and cost-effectiveness scatterplots were
used for comparison. RESULTS: No differences were found in
acute treatment effectiveness (GR = 78.7%, ON = 79%) making
impossible to interpret ICER values. Direct mean cost was some-
what higher for GR = 36.9€ (SD = 35.3) than for ON = 34.1€
(SD = 34.2). Delayed effectiveness was higher in GR (51.8%)
than in ON (42.7%) arm, with lower mean (90%IC) costs in
GR = 19.54€ (16.57, 22.6) than in ON = 55.26€ (46.4, 64.2)
group. Bootstrap ICER mean value was 353.1 (P10 = 1120.8,
P90 = 85.7). Scatterplots in the cost-effectiveness space showed
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